LEADER 02816nam  2200673Ia 450 
001 996217305103316
005 20240410133942.0
010   $a1-280-01137-8
010   $a9786610011377
010   $a0-585-49272-7
010   $a92-4-068153-1
035   $a(CKB)1000000000008536
035   $a(EBL)284791
035   $a(OCoLC)191039474
035   $a(SSID)ssj0000271404
035   $a(PQKBManifestationID)11253775
035   $a(PQKBTitleCode)TC0000271404
035   $a(PQKBWorkID)10295697
035   $a(PQKB)11709562
035   $a(MiAaPQ)EBC284791
035   $a(Au-PeEL)EBL284791
035   $a(CaPaEBR)ebr10047391
035   $a(CaONFJC)MIL1137
035   $a(OCoLC)55664162
035   $a(EXLCZ)991000000000008536
100   $a20040211d2003      my         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aWHO Expert Committee on Drug Dependence$b[electronic resource] $ethirty-third report
205   $a1st ed.
210   $aGeneva $cWorld Health Organization$d2003
215   $a1 online resource (31 p.)
225 1 $aWHO technical report series ;$v915
300   $aDescription based upon print version of record.
311   $a92-4-120915-1 
327   $aContents; 1. Introduction; 2. Scheduling criteria; 3. Critical review of psychoactive substances; 4. Pre-review of psychoactive substances; 5. Terminology used in reporting abuse-related adverse drug reactions; 6. Other matters; Acknowledgements; References; Annex Terminology used in reporting abuse-related adverse drug reactions; References;
330   $aThis report presents the recommendations of a WHO Expert Committee responsible for reviewing information on dependence-producing drugs to assess the need for their international control. The first part of the report contains a summary of the Committee's evaluations of seven substances (dronabinol, oripavine, buprenorphine, butorphanol, ketamine, khat and zopiclone). The report also discusses the substances that were pre-reviewed (gamma-hydroxybutyric acid and tramadol) and recommended gamma-hydroxybutyric acid for critical review at a future meeting. Two substances (gamma-butyrolactone and 1,4
410  0$aTechnical report series (World Heald Organization) ;$v915.
606   $aSubstance abuse
606   $aDrug abuse
606   $aDesigner drugs
606   $aStereoisomers
606   $aEphedrine
615  0$aSubstance abuse.
615  0$aDrug abuse.
615  0$aDesigner drugs.
615  0$aStereoisomers.
615  0$aEphedrine.
676   $a362.29
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a996217305103316
996   $aWHO Expert Committee on Drug Dependence$92025022
997   $aUNISA